Large Molecule Drug Substance CDMO Market Projected to Grow 9% Annually Through 2031

The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period. This growth is primarily driven by the rising demand for biologics and biosimilars, advancements in bioprocessing technologies, an increasing number of FDA and EMA approvals for large molecule drugs, the growing prevalence of chronic and infectious diseases, greater investment in biologics manufacturing by pharmaceutical and biotechnology companies, and the rapid expansion of biotech industries in emerging markets.

Large molecule drug substances, also known as biologics, are complex therapeutics produced using living cells. These include monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell-based treatments. A Contract Development and Manufacturing Organization (CDMO) provides outsourced expertise and infrastructure to support drug development and production. Their services encompass cell line development, process optimization, upstream and downstream processing, formulation, analytical testing, and regulatory compliance.

The demand for biologic therapies, particularly antibody-based treatments, continues to rise owing to their effectiveness in targeting and managing complex and rare diseases such as cancer, Crohn's disease, multiple sclerosis, and cystic fibrosis. Large-molecule drugs are typically administered parenterally due to their structural sensitivity and complexity, making their development and manufacturing significantly more challenging than small-molecule drugs.

The expiration of patents for blockbuster biologics has spurred rapid growth in the biosimilar market as pharmaceutical companies pursue cost-effective alternatives to high-priced biologic drugs. Regulatory agencies such as the FDA and EMA have streamlined approval pathways for biosimilars, accelerating their market entry and increasing the need for specialized large-molecule manufacturing capabilities. Patent expirations for blockbuster biologics such as Humira, Herceptin, and Avastin have further accelerated biosimilar development, boosting competition and reducing healthcare costs.

To expedite patient access to innovative therapies, regulatory agencies have introduced accelerated approval mechanisms. Programs such as the FDA's Breakthrough Therapy Designation, Fast Track, and Priority Review, along with the EMA's PRIME (Priority Medicines) designation, have significantly reduced approval timelines for promising biologics. The increasing number of orphan drug approvals further highlights this momentum, particularly for treatments targeting rare and ultra-rare conditions.

According to a June 2024 report, over half of FDA and EMA approvals in Q2 2024 were for biologics or biosimilars—demonstrating the strong regulatory and commercial shift toward large-molecule drugs.

Contract Development and Manufacturing Organizations play a critical role in this market. Equipped with state-of-the-art facilities, advanced technologies, and highly skilled personnel, CDMOs provide the expertise required for the complex processes involved in biologics and biosimilar production. As adoption of biologic therapies expands across the pharmaceutical industry, CDMOs enable scalable, cost-efficient, and regulatory-compliant manufacturing.

The global large molecule drug substance CDMO market features a mix of established and emerging players, including Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, Thermo Fisher Scientific, and FUJIFILM Diosynth Biotechnologies.